First Global R&D Initiative Since Transition to Bio Investment Holding Company

Samsung Epis Holdings, the bio investment holding company of Samsung, has officially launched its research and development (R&D) hub in China, aiming to strengthen its capabilities in new drug development.


Paik Kyung-ah, President of Samsung Epis Holdings (6th from the left), and key guests are attending the opening ceremony of the China R&D center and taking a commemorative photo. Samsung Epis Holdings

Paik Kyung-ah, President of Samsung Epis Holdings (6th from the left), and key guests are attending the opening ceremony of the China R&D center and taking a commemorative photo. Samsung Epis Holdings

View original image

Samsung Epis Holdings announced on July 1 that it held the opening ceremony for 'Samsung Bioepis (China) Co., Ltd.' on June 30 in Changping District, Beijing, China, and has begun full-scale R&D activities.


The China R&D center is Samsung Epis Holdings' first overseas research and development hub, established to secure next-generation bio technology platforms such as antibody-drug conjugates (ADCs) and to enhance its capabilities in new drug development. The company plans to utilize local research infrastructure and the bio ecosystem to expand the discovery of innovative drug candidates.


Changping District in Beijing, where the center is located, is home to the Zhongguancun Life Science Park, an advanced bio technology industrial complex. The area is considered advantageous for securing outstanding research talent and infrastructure, as it is adjacent to major research institutions such as Peking University and Tsinghua University.



Kim Kyung-Ah, President of Samsung Epis Holdings, said, "With the opening of the China R&D Center, we have taken the first step towards establishing a global R&D network. We will continue to expand our new business by closely collaborating with the Chinese bio ecosystem to discover innovative drug candidates."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing